Chemotherapy for gastric carcinoma: new and old options.
Although gastric carcinoma is an uncommon disease in North America, its incidence is alarmingly high in Asia, South America, Eastern Europe, and countries of the former Soviet Union. Screening for gastric carcinoma is performed only on a limited basis in Japan; in the rest of the world, therefore, patients often present with advanced disease at the time of diagnosis. Chemotherapy, radiotherapy, or both rarely cure patients with unresectable or metastatic carcinoma; therapy thus remains palliative for such patients. Chemotherapy seems to be beneficial, however, and continues to evolve in the treatment of patients with advanced gastric carcinoma. Four small randomized trials demonstrated survival and quality-of-life benefits for patients who received chemotherapy compared with those who received best supportive care. In the past 20 years, several "old" drugs have been studied either alone or in combination to treat this disease; and new active drugs have been identified. Recently, quality of life, convenience, and cost-containment have been emphasized in the treatment of cancer. This has increased interest in oral agents. At present, several promising oral 5-fluorouracil prodrugs are being studied in clinical trials. This article summarizes current developments in the treatment of advanced gastric carcinoma.
Ajani
J A
JA
Department of Gastrointestinal Oncology and Digestive Diseases, University of Texas, M. D. Anderson Cancer Center, Houston, USA.
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D004338:Drug Combinations; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D010094:Oxonic Acid / Q000008:administration & dosage / Q000737:chemistry; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives; D011725:Pyridines / Q000008:administration & dosage / Q000737:chemistry; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy*; D043823:Taxoids; D005641:Tegafur / Q000008:administration & dosage / Q000737:chemistry; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D011725:Pyridines; D043823:Taxoids; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; C073482:eniluracil; D014498:Uracil; D010094:Oxonic Acid; D000069287:Capecitabine; D005047:Etoposide; D000077146:Irinotecan; D017239:Paclitaxel; D005472:Fluorouracil; D002166:Camptothecin